Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. - Wikidata - wikimedia - TriplyDB

Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.

Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.

http://www.wikidata.org/entity/Q35127882

about

Alternative pre-approved and novel therapies for the treatment of anthrax Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children Levofloxacin cures experimental pneumonic plague in African green monkeys.Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus).Combination therapy with antibiotics and anthrax immune globulin intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax.Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults Immunoassay for Capsular Antigen of Bacillus anthracis Enables Rapid Diagnosis in a Rabbit Model of Inhalational Anthrax.Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.Pathology and pathophysiology of inhalational anthrax in a guinea pig model.Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.Macaque models of human infectious disease.Progress and prospects for genetic modification of nonhuman primate models in biomedical research.The animal rule and emerging infections: the role of clinical pharmacology in determining an effective dose.Antimicrobials for bacterial bioterrorism agents.Modeling and simulation in dose determination for biodefense products approved under the FDA animal rule.Antibiotics cure anthrax in animal models.The animal rule: The role of clinical pharmacology in determining an effective dose in humans.Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.

P2860

Q28075453-6A2F90F9-0A3D-40D4-9CB0-80D2175111FE Q28384759-80CC14ED-2AD2-47F8-98CB-34950EC40254 Q28385233-912C3A60-2BBE-43F7-866A-ECA48668F36A Q33559117-055F8935-69BD-4839-AC4F-7E00DFC2E842 Q33828874-BE145F5E-0659-48AA-94F7-A418DD493F3D Q34108623-AD5FB6D1-1119-4449-97FA-E33130C05A4B Q34194627-95DA3C52-DDCD-4752-A370-4F16EFC716E0 Q34368520-19F9974D-6FD2-4ABF-881D-29CC7AC2E1E6 Q34602462-533EB85C-3B02-4B08-B36A-07076394DE7C Q35571163-240A763F-6A44-4735-8DE7-3208B5166CFB Q35806278-9A80C52E-0303-441E-ADFA-892CB33DEAF2 Q35912654-33C1E4AD-FE2D-40D7-8A1B-1BCA243F309D Q36586760-7DE9A8D5-3935-4257-98EA-00F805A40321 Q36804713-DCA03445-E7E8-4541-8666-CBD5784CCD8B Q36970295-91B17AE4-50BB-4ACA-8956-392AE11C5317 Q37103536-12A6A9F3-8161-4405-9274-0E355612EDCF Q37271259-A080EBAE-7D02-46C3-9B67-3F8A1F81D9CE Q37538531-7A580458-E36B-4084-BAE7-3287FFFF79BD Q37894696-789BAFD1-932A-43BD-AD48-7D5AB995418F Q39181299-854F9C70-C8C6-4371-9B65-64C747D99B08 Q41890173-AEAA0A01-90D3-4A75-AD38-F212FE1B31F7 Q46714015-F48C82D3-B3EC-4B34-BC0C-C7CBBA7AAC5A Q46936728-F3273BDA-1306-44F1-938E-447FBAEE762A

P2860

Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.

http://www.wikidata.org/entity/Q35127882

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Pharmacokinetic considerations ...... exposure) rhesus monkey model.

@ast

Pharmacokinetic considerations ...... exposure) rhesus monkey model.

@en

type

label

Pharmacokinetic considerations ...... exposure) rhesus monkey model.

@ast

Pharmacokinetic considerations ...... exposure) rhesus monkey model.

@en

prefLabel

Pharmacokinetic considerations ...... exposure) rhesus monkey model.

@ast

Pharmacokinetic considerations ...... exposure) rhesus monkey model.

@en

P1433

Q35127882-6B3459A7-487B-46B6-9508-7D2E920D2ED3

P1476

Q35127882-F785EF51-921C-42F4-A67E-96A201933B03

P2093

Q35127882-08C74B89-EEFE-413B-A473-4CD96F9F3D4D

Q35127882-2217AAE1-6068-4098-A618-C422F0807BC8

Q35127882-27481BC0-776E-41E9-A30F-C02E0B55F37A

Q35127882-4189F918-8A1C-48ED-97C0-5EE5D6004DDC

Q35127882-848EC71F-0365-44CD-8345-69E51748CBF9

Q35127882-A280F3C5-9826-4D17-97BE-04723E49F05A

Q35127882-AEFEF870-B4E3-44AD-B3F1-249496B1B5C0

Q35127882-B74E9C2E-FF7F-4743-AABE-02DF23991487

Q35127882-C907BA47-D9F8-4451-8C50-7473650217FF

Q35127882-D84FF6DD-4191-41FF-BA49-2EB51FF7FA57

P2860

Q35127882-1CEAA057-5898-4336-891E-076910669E55

Q35127882-299C84FB-35A7-44AF-AFE0-4B8DD6DBC9C9

Q35127882-2C731B70-0DFA-4B53-B4C9-37904D84E183

Q35127882-35D61FE8-47B5-42BD-AA53-10EFAD6B649A

Q35127882-3B4D8732-E874-4C2F-901F-1081E409EADE

Q35127882-3CA21A92-5FE0-4CA2-A3DA-A4068ED9ED97

Q35127882-46CFD395-7D59-4A74-BE1D-A59A6F00AD96

Q35127882-51648007-B7E4-46B3-B2F6-A1FAB0778595

Q35127882-56DE859C-FB1D-4EE2-9364-A4D08F487840

Q35127882-B2DA646A-EBDB-4CC2-9658-7C4609F13D72

P304

Q35127882-F747A10D-47B1-4B5A-B558-A4596500889E

P31

Q35127882-77AF530D-CF5F-4BB9-9B4B-5160F4CD8040

P356

Q35127882-C62C82AA-13D5-4A36-AE62-672A2ED56CC3

P407

Q35127882-8C8ECD5F-B184-4372-B17B-AA8F68BFB463

P433

Q35127882-C9531562-42E8-4A8B-9129-3F98B03DCE63

P478

Q35127882-2E66F307-842D-4E8D-9A1C-45CC6EA075A9

P577

Q35127882-5E4DF8B3-D21D-465C-A159-32E80C4BF43B

P5875

Q35127882-54BD16A7-ADEC-487D-AF03-0D9CE6A0B400

P698

Q35127882-C3D6CE8D-912B-47CE-BF59-FF50C5027483

P932

Q35127882-490862C1-F62D-404D-8847-C974BD52E4DE

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetic considerations ...... exposure) rhesus monkey model.

@en

P2093

Alex Hemeryck

http://www.w3.org/2001/XMLSchema#string

Frederic W Thalacker

http://www.w3.org/2001/XMLSchema#string

George L Drusano

http://www.w3.org/2001/XMLSchema#string

James Estep

http://www.w3.org/2001/XMLSchema#string

Karen Bush

http://www.w3.org/2001/XMLSchema#string

L Mark Kao

http://www.w3.org/2001/XMLSchema#string

Michael F Kelley

http://www.w3.org/2001/XMLSchema#string

Neil Minton

http://www.w3.org/2001/XMLSchema#string

Pamela H Olson

http://www.w3.org/2001/XMLSchema#string

Roy Barnewall

http://www.w3.org/2001/XMLSchema#string

P2860

Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000.

Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods

Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.

Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'.

PATHOLOGY OF EXPERIMENTAL RESPIRATORY ANTHRAX IN MACACA MULATTA.

The clinical pharmacokinetics of levofloxacin.

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

Observations on the prophylaxis of experimental pulmonary anthrax in the monkey.

Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys.

P304

3535-3542

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00090-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6729867

http://www.w3.org/2001/XMLSchema#string

P698

17065619

http://www.w3.org/2001/XMLSchema#string

P932

1635218

http://www.w3.org/2001/XMLSchema#string